Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients

Nilotinib is a tyrosine kinase inhibitor that is safe and tolerated in neurodegeneration, it achieves CSF concentration that is adequate to inhibit discoidin domain receptor (DDR)-1. Nilotinib significantly affects dopamine metabolites, including Homovanillic acid (HVA), resulting in an increase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Karen E., Stevenson, Max, Varghese, Rency, Hebron, Michaeline L., Koppel, Erin, McCartin, Mara, Kuprewicz, Robin, Matar, Sara, Ferrante, Dalila, Moussa, Charbel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781133/
https://www.ncbi.nlm.nih.gov/pubmed/36557263
http://dx.doi.org/10.3390/metabo12121225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781133/
https://www.ncbi.nlm.nih.gov/pubmed/36557263
http://dx.doi.org/10.3390/metabo12121225

Ejemplares similares